Synact Pharma

biotech company based in Sweden

Nasdaq Stockholm ISIN SE0008241491 LEI 549300RRYIEFEQ72N546
Follow Synact Pharma Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 SEK · IFRS
Revenue, last year SEK 0
Net income −SEK 110.8M −34.5% vs prior year
EPS, diluted −SEK 2.17 −4.3% vs prior year
Operating cash flow −SEK 97.3M −9.1% vs prior year
Revenue by fiscal year
SEK 0
SEK 0
SEK 0
SEK 0
SEK 0
FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−SEK 300M−SEK 200M−SEK 100MSEK 0FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25SEK 0−SEK 110.8M
FY24SEK 0−SEK 82.4M
FY23SEK 0−SEK 215.8M
FY22SEK 0−SEK 99.2M
FY21SEK 0−SEK 69.3M